Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide
Open Access
- 30 June 1998
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 31 (7), 1518-1524
- https://doi.org/10.1016/s0735-1097(98)00130-2
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-IIThe Lancet, 1997
- Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary InterventionCirculation, 1995
- Morbidity and mortality rates in elderly patients undergoing percutaneous coronary transluminal angioplastyAmerican Heart Journal, 1994
- A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1994
- A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery DiseaseNew England Journal of Medicine, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Vascular complications of cardiac catheterizationThe American Journal of Surgery, 1994
- Vascular complications after balloon and new device angioplasty.Circulation, 1993
- Peripheral vascular complications after conventional and complex percutaneous coronary interventional proceduresThe American Journal of Cardiology, 1992
- Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplastyJournal of Vascular Surgery, 1990